MentiNova Inc.
Repurposed drug treats L-dopa-induced dyskinesia
This article was originally published in Start Up
Executive Summary
For the past 50 years, levodopa, a dopamine precursor, has been the gold-standard treatment for people with Parkinson’s disease-, but there is a significant downside---a condition known as L-dopa-induced dyskinesia that emerges after using this medication for some time. MentiNova Inc., a clinical-stage, New Jersey-based biotechnology company, is repurposing the analgesic nalbuphine for the treatment of LID.
You may also be interested in...
Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
Quartet Medicine Inc.
Quartet Medicine Inc.'s pipeline of novel small-molecule drugs to address chronic pain and inflammation target the tetrahydrobiopterin (BH4) synthesis pathway, a target with genetic and pharmacological links to regulating human disease at the intersection of the peripheral nervous system and the immune system. The start-up thinks its approach has the potential to provide improved efficacy without the side effects associated with existing centrally acting analgesics.
ObsEva SA
Despite many improvements in the last 25 years, there continue to be serious unmet medical needs in the area of reproductive health. ObsEva SA, a clinical-stage biopharmaceutical company based in Geneva, Switzerland, aims to address some of those needs with novel oral drugs for three highly prevalent reproductive health-related challenges: endometriosis, pre-term labor, and repeated implantation failure in women undergoing in vitro fertilization.